The Medicine Box By cover art

The Medicine Box

By: CNBC-TV18
Listen for free

  • Summary

  • A podcast designed to put the spotlight on the most important issues in the pharmaceutical and healthcare space — hosted by Ekta Batra. #TheMedicineBox provides a sharper vision of the future of the pharma and healthcare industry to see where it is headed.
    Show more Show less
activate_primeday_promo_in_buybox_DT
Episodes
  • 40: The Medicine Box: Zydus Lifesciences MD Sharvil Patel on rebranding after nearly 3 decades

    40: The Medicine Box: Zydus Lifesciences MD Sharvil Patel on rebranding after nearly 3 decades
    Apr 20 2022
    An Indian pharma company has rebranded itself after almost three decades, 27 years. A firm that is ranked fourth in the Indian pharma industry, fifth in the US generics market via prescriptions and has been at the forefront of fighting COVID-19 by introducing one of the cheapest versions of Remdesivir and more.

    The firm Cadila Healthcare (now known as Zydus Lifesciences) has many feathers on its hat, however, its challenges included the offtake of the COVID-19 vaccine and the long gestations and investments required to become an innovative company amid growing competition in the US.

    To discuss this and more, CNBC-TV18’s Ekta Batra caught up with Zydus Lifesciences’ managing director Sharvil Patel.

    Patel shares the significance of the new name, the firm's plans to be defined as a global life sciences company with a focus on innovation and its generics business.

    Tune in to The Medicine Box Podcast for more

    In case you have any queries or suggestions, please write to us at cnbctv18podcast@nw18.com
    Show more Show less
    20 mins
  • 39: The Medicine Box: Cipla’s Umang Vohra on COVID-19 portfolio, upcoming drugs, US business outlook and more

    39: The Medicine Box: Cipla’s Umang Vohra on COVID-19 portfolio, upcoming drugs, US business outlook and more
    Apr 2 2022
    Pharma industry’s Robinhood, Cipla is looking to increase its presence in the US market, the company’s MD and Global CEO Umang Vohra.

    In this edition of The Medicine Box Podcast, CNBC-TV18’s Ekta Batra talks to Vohra about Cipla’s plan to capture a larger share of the US market, the firm’s COVID-19 portfolio – from Tocilizumab to Remdesivir to Favipiravir, new products, growth outlook and more.

    Cipla, which is India’s third largest pharma company and is present in more than 80 countries with over 46 manufacturing facilities, is looking to manufacture complex drugs and injectables in respiratory and cancer segments, Vohra said.

    Tune in to The Medicine Box Podcast for more 
    Show more Show less
    21 mins
  • 38: The Medicine Box: Torrent Pharma eyes double digital domestic growth, cardiology key focus, says ED Aman Mehta

    38: The Medicine Box: Torrent Pharma eyes double digital domestic growth, cardiology key focus, says ED Aman Mehta
    Mar 29 2022
    Torrent, an over 60-year-old Indian pharma company, the flagship company of the Torrent Group, is most recognised for its strong domestic focus. It is the eighth largest player in India, with around 40 percent of its revenues from the domestic market.

    It has strengthened its presence with acquisitions in the past 10 years such as buying Elder Pharma’s domestic business in 2014 for Rs 2000 crore and Unichem’s domestic business in 2017 for Rs 3600 crore. Domestic market brands include Shelcal, Unienzyme and Nebicard.

    In this edition of The Medicine Box Podcast, CNBC-TV18’s Ekta Batra gets in conversation with Torrent Pharma’s ED Aman Mehta to know more about the company’s outlook for growth on the domestic as well as the global front.

    The company expects underlying domestic growth in double digits whilst seeing quarterly blips. Cardiology is a focus area for the company, which is ranked second in the cardiac segment and expects to grow in double digits.

    One of its key brands, Shelcal has shown robust growth in the past few years with a focus on newer extensions in the brand.

    Outside of India, the company is looking at remediation measures for plants impacted by USFDA issues and anticipates a 10 percent price erosion in the US. The company has also recently entered newer markets such as Mexico.

    Overall, it expects margins to recover to 28-30 percent and is looking at mid sized acquisitions.

    Tune in to The Medicine Box Podcast for more
    Show more Show less
    21 mins
Economics Science
Show more Show less

What listeners say about The Medicine Box

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available